Document:

Exhibit
10.64

 

MATERIALS TRANSFER AGREEMENT

 

This Agreement is among Advanced Cell
Technology, Inc. (“ACT”), Philip Damiani Ph.D. (“The Institution”) and  CARLOS T. MORAES Ph.D. (“Researcher”).
 The Institution and the Researcher are
collectively referred to in this Agreement as the “Recipients.”

 

The parties hereby agree as follows:

 

1.              Requested
Materials. The term “Materials” shall mean the following
tangible materials that are requested by Researcher and furnished by ACT under
the terms of this Agreement:

 

Gaur fetal tissue—brain, tongue, tongue/lower
jaw, heart, intestine, liver, kidney, skin, muscle (leg), eye, hind foot (hoof)

 

ACT 00-011 cell line—bovine adult male
holstein

 

ACT 00-014 cell line gaur adult male

 

samples gaur 1-6; cow 1-4

 

“Materials” shall also include any other
materials routinely produced through use of such tangible materials, including,
for example, any progeny derived from a cell line, monoclonal antibodies
produced by hybridoma cells, DNA or RNA replicated from isolated DNA or RNA,
recombinant proteins produced by a recombinant cell line, recombinant proteins
produced through use of isolated DNA or RNA, and substances routinely purified
from any source material included in the materials (such as recombinant
proteins isolated from a cell extract or supernatant by non-proprietary
affinity purification methods).

 

2.                Limited Use of Materials. The
Recipients agree to use the Materials only for the following experimental
research under the direct supervision of Researcher, and not for any other
purpose:

 

Mitochondria Evaluation

 

DNA Markers

 

The Recipients shall use the Materials only
in compliance with all applicable federal, state and local laws and
regulations. The Recipients shall not use the Materials in any in vivo experiments
on human subjects without the prior written consent of ACT

 

 

3.               Limited Disposition of Materials.   The Materials shall remain on the premises of
the Institution. The Recipient shall not distribute any Materials to any third
party other than employees or students of Institution who are working under the
supervision of Researcher. Upon completion of the research, or sooner at the
request of ACT, the Recipient shall at the instruction of ACT either destroy or
return any unused Materials.

 

4.               Ownership of Materials.   The Recipient acknowledges and agrees that
all title and intellectual property rights in the Materials are and shall be
owned by ACT. The Recipient agrees to execute and deliver and documents of
assignment or conveyance to effectuate the ownership rights of ACT in the
Materials.

 

5.               Ownership of Intellectual Property.   The Researcher shall promptly inform ACT
they intend to commercialize, to file a patent application claiming, or to
assert any intellectual property rights in any research results obtained using
the Materials. ACT agrees to negotiate in good faith their respective ownership
of the research results and any intellectual property rights therein based on
their relative contributions to such rights and on any applicable laws relating
to ownership of such rights, including without limitation those relating to
inventorship and authorship.

 

6.               License Option to ACT.   Recipients shall notify ACT promptly of any
discoveries, inventions, data, modifications, new substances, and other results
of any research using the Materials (“Research Results”).    To the extent permitted by law and any
conflicting obligations to non-profit sponsors of research, the Recipient
hereby grants ACT a first option to obtain an exclusive, worldwide license
under any intellectual property rights in any Research Results (the “License
Option”).   ACT may exercise the License
Option upon written notice and the Recipient within thirty (30) days from the
date upon which ACT receives notice of the relevant Research Results. In the
event that ACT elects to exercise the License Option, the parties shall attempt
to negotiate in good faith to license agreement containing commercially
reasonable terms and pricing.   If the
parties are unable to reach agreement within ninety (90) days after the date
upon which ACT exercised the license option (the “Negotiation Period”).   Then the Recipient will be free to offer
such rights to third parties; provided, however, that for a period of one (1)
year after the Negotiation Period

 

2

 

the Recipient may only offer such rights to third
parties on terms and pricing which in the aggregate are no more favorable than
those last offered to ACT, unless the more favorable terms and pricing have
first been offered in writing to ACT and either (i) ACT has declined in writing
to accept such terms and pricing or (ii) ACT has not responded after a period
of thirty (30) days from the date of such offer. The Recipient shall not use
the Materials in research that is subject to a licensing obligation to another
commercial entity without the prior written consent of ACT.

 

7.               Publication Rights. Researcher shall have the unrestricted right
to publish the results of any research using the Materials; however, in order
to prevent the inadvertent loss of patent rights, the Recipients shall provide
ACT with pre-prints or abstracts of any proposed presentation or paper
describing any Research Results at least sixty (60) days prior to publication.

 

8.              No Warranties. 
Any Materials
delivered pursuant to this Agreement are understood to be experimental in
nature and may have hazardous properties.  ACT MAKES NO REPRESENTATIONS
AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. WITH RESPECT
TO THE MATERIALS, AND SPECIFICALLY DISCLAIMS ANY IMPLIED WARRANTIES OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIALS WILL NOT
INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF A THIRD PARTY.

 

9.               Indemnification. The Recipient assumes all liability for
damages which may arise from the use, storage, or disposal of the Materials. To
the extent permitted by applicable law, ACT agrees to indemnify, defend, and
hold harmless its directors, officers, representatives, employees, and agent
gains all losses, expenses (including without limitation any legal expenses),
claims, demands, suits, or other actions arising from the use, storage, or
disposal of the Materials by the Recipient, except to the extent caused by the
recklessness or willful misconduct of ACT.

 

3

 

The
parties hereby execute this Agreement effective as the date last written below.

 

 

	
  INSTITUTION

  	
  RESEARCHER

  
	
   

  	
   

  
	
   

  	
   

  
	
  By: 

  	
  /s/ Tom Gill

  	
   

  	
  By:  

  	
  /s/ Carlos
  T. Moraes

  	
   

  
	
  Name:

  	
  TOM
  GILL

  	
   

  	
  Name:

  
	
  Title: 

  	
  DIRECTOR
  OF RESEARCH ADMINISTRATION

  	
   

  	
  Title: 

  
	
  Date:

  	
  2/23/00

  	
   

  	
  Date:

  	
  2/23/00

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  ADVANCED CELL TECHNOLOGY

  	
  Carlos T. Moraes, Ph.D.

  	
   

  
	
   

  	
  Dept. of Neurology-UMSM

  	
   

  
	
   

  	
  1501 N.W. 9th Avenue

  	
   

  
	
  By: 

  	
  /s/ Jose B.
  Cibelli

  	
   

  	
  Miami, Florida 33136

  	
   

  
	
  Name:

  	
  Jose B.
  Cibelli, Ph.D.

  	
   

  
	
  Title: 

  	
  Vice
  President of Research

  	
   

  
	
  Date:

  	
   

  
									

 

4Exhibit 10.65

 

UNIVERSITY OF MASSACHUSETTS

ADVANCED CELL TECHNOLOGY

MATERIALS TRANSFER AGREEMENT

 

This Agreement
is among the University of Massachusetts (“UMass”), Advanced Cell Technology,
Inc. (“ACT”), University of Colorado (the “Institution”), and Curtis R. Freed,
M.D. (“Researcher”).  The Institution and
the Researcher are collectively referred to in this Agreement as the “Recipients.”

 

UMass believes
that tangible research materials should be made freely available among academic
institutions for noncommercial research. 
However, UMass has granted an exclusive license to ACT to use the
tangible research materials exchanged under this Agreement for commercial
purposes.  Although UMass has the right
to transfer these materials for noncommercial research without ACT approval,
UMass recognizes that ACT has a legitimate interest in preserving commercial
rights in discoveries that may arise through academic use of the
materials.  UMass has therefore altered
its standard form Academic Materials Transfer Agreement to accommodate the
legitimate commercial interests of ACT while maintaining the free exchange of
tangible research materials for noncommercial, academic research.

 

The parties
hereby agree as follows:

 

1. Requested Materials.  The term “Materials” shall mean the following
tangible materials that are requested by Researchers and furnished by UMass
under the terms of this Agreement:

 

Bovine fetuses (30-60 days of
gestation).  These fetuses will be
derived from fertilized embryos, nuclear transfer embryos and/or nuclear
transfer transgenic embryos.  In some
cases, fetal tissue from the above embryos

 

 

“Materials” shall also include
any other materials routinely produced through use of such tangible materials,
including, for example, any progeny derived from a cell line, monoclonal antibodies
produced by hybridoma cells, DNA or RNA replicated from isolated DNA or RNA, recombinant
proteins produced by a recombinant cell line, recombinant proteins produced
through use of isolated DNA or RNA, and substances routinely purified from any
source material included in the materials (such as recombinant proteins isolated
from a cell extract or supernatant by non-proprietary affinity purification
methods).

 

2. Limited Use of Materials.
The Recipients agree to use the Materials only for the following experimental
research under the direct supervision of Researcher, and not for any other
purpose:

 

Determine tyrosine hydroxylase activity in neural cells (bovine).

Determine grafting of neural cells (bovine) in Rat models.

 

The Recipients shall use the Materials only in compliance with all
applicable federal, state, and local laws and regulations.  The Recipients shall not use the Materials in
any in vivo experiments on human subjects without the prior written
consent of UMass.

 

3. Limited Disposition of Materials.  The Materials shall remain on the premises of
the Institution.  The Recipients shall
not distribute any Materials to any third party other than employees or
students of Institution who are working under the supervision of Researcher.
Upon completion of the

 

 

research or sooner at the request of UMass, the Recipients shall at the
instruction of UMass either destroy or return any unused Materials.

 

4. Ownership of Materials. The Recipients acknowledge and agree
that all title and intellectual property rights in the Materials are and shall
be owned by UMass. The Recipients agree to execute and deliver any documents of
assignment or conveyance to effectuate the ownership rights of UMass in the Materials.

 

5. Ownership of Intellectual Property. The Institution and
Researcher shall promptly inform UMass if either intends to commercialize, to
file a patent application claiming, or to assert any intellectual property
rights in any research results obtained using the Materials. UMass and the
Institution agree to negotiate in good faith their respective ownership of the research
results and any intellectual property rights therein based on their relative
contributions to such rights and on any applicable laws relating to ownership
of such rights, including without limitation those relating to inventorship and
authorship.

 

6. License Option to ACT. Recipients shall notify ACT promptly
of any discoveries, inventions, data, modifications, new substances, and other
results of any research using the Materials (“Research Results”). To the extent
permitted by law and any conflicting obligations to non-profit sponsors of
research, the Recipients hereby grant ACT a first option to obtain an
exclusive, worldwide license under any intellectual property rights in any
Research Results (the “License Option”). ACT may exercise the License Option
upon written notice to the Recipients within thirty (30) days from the date
upon which ACT receives notice of the relevant Research Results. In the event
that ACT elects to exercise the License Option, the parties shall attempt to
negotiate in good faith a license agreement containing commercially reasonable
terms and pricing. If the parties are unable to reach agreement within ninety
(90) days after the date upon which ACT exercised the license option (the “Negotiation
Period”), then the Recipients will be free to offer such rights to third
parties; provided, however, that for a period of one (1) year after the
Negotiation Period, the Recipients may only offer such rights to third parties
on terms and pricing which in the aggregate are no more favorable than those
last offered to ACT, unless the more favorable terms and pricing have first
been offered in writing to ACT and either (i) ACT has declined in writing to
accept such terms and pricing or (ii) ACT has not responded after a period of
thirty (30) days from the date of such offer. The Recipients shall not use
Materials in research that is subject to a licensing obligation to another
commercial entity without the prior written consent of ACT.

 

7. Publication Rights. Researcher shall have the unrestricted
right to publish the results of any research using the Materials; however, in
order to prevent the inadvertent loss of patent rights, the Recipients shall
provide ACT with pre-prints or abstracts of any proposed presentation or paper
describing any Research Results at least sixty (60) days prior to publication.

 

8. No Warranties. Any Materials delivered pursuant to this
Agreement are understood to be experimental in nature and may have hazardous
properties. UMASS MAKES NO REPRESENTATIONS, AND EXTENDS
NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. WITH RESPECT TO THE
MATERIALS, AND SPECIFICALLY DISCLAIMS ANY IMPLIED WARRANTIES OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIALS WILL NOT
INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF A THIRD PARTY.

 

2

 

9. Indemnification. The Recipients assume all liability for damages
which may arise from the use, storage, or disposal of the Materials.  To the extent permitted by applicable law,
the Institution agrees to indemnify, defend, and hold harmless UMass and its
directors, officers, representatives, employees, and agents against all losses,
expenses (including without limitation any legal expenses), claims, demands,
suits, or other actions arising from the use, storage, or disposal of the
Materials by the Recipients, except to the extent caused by the recklessness or
willful misconduct of UMass.

 

The parties hereby execute this Agreement effective as of the date last
written below.

 

	
  INSTITUTION

  	
  RESEARCHER

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ 

  	
   

  	
  /s/ Curt R. Freed

  	
   

  
	
  Name: University of Colorado, Health Sci. Ctr.

  	
  Name: Curt R. Freed, M.D.

  
	
  Title: DIRECTOR

  	
  Date: January 6, 1997

  
	
  Date: January 6, 1997

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  UNIVERSITY OF MASSACHUSETTS

  	
  ADVANCED CELL TECHNOLOGY, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ E. Bradley Moynahan

  	
   

  	
  By:

  	
  /s/ Steven L. Stice

  	
   

  
	
  Name: E. Bradley Moynahan

  	
  Name: Steven L. Stice

  
	
  Title: Dir. Commercial Ventures / Intellectual Property UM/Amherst

  	
  Title: Vice President, Research & Development

  
	
  Date: January 2, 1997

  	
  Date: January 2, 1997

  
						

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}]]